Indenyl compounds, pharmaceutical compositions, and medical uses thereof
Disclosed are compounds, for example, compounds of formula I, wherein R, R 0 , R 1 -R 8 , n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
1. A compound, (Z)- or (E)-isomer thereof, of formula IIa:
wherein:
R 1 , R 2 , R 3 , R 4 , R 13 and R 15 are independently selected from hydrogen, halogen, alkyl, cycloalkyl, haloalkyl, and alkoxy;
R 7 and R 8 are independently selected from hydrogen, alkyl, haloalkyl and alkoxy;
R 14 is of the formula Q-U— wherein U is selected from the group consisting of oxygen, sulfur, OCH 2 , SCH 2 and NHCH 2 ; and Q is selected from the group consisting of PEG-CO, amino acid, substituted benzoic acid and phosphoric acid; or, wherein Q-U together is a substituted or unsubstituted group selected from phosphonooxy, phosphonoalkyloxy, alkylcarbonyloxyalkyloxy, aminocarbonyloxyalkyloxy, arylcarbonyloxy, arylalkylcarbonyloxy, aryloxycarbonyloxy, heterocyclylcarbonyloxy and heterocyclylalkylcarbonyloxy;
R′ is selected from furanyl and furanylalkyl wherein the furanyl of the furanyl and furanylalkyl is optionally substituted with one or more of halo, alkyl, haloalkyl, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, mercapto, alkylmercapto, carboxamido, aldehydo, cyano, oxo, alkylcarbonyloxy, and sulfonamido;
or, a pharmaceutically acceptable salt thereof.
2. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein R 14 is a substituted or unsubstituted group selected from phosphonooxy, phosphonoalkyloxy, alkylcarbonyloxyalkyloxy, aminocarbonyloxyalkyloxy, arylcarbonyloxy, arylalkylcarbonyloxy, aryloxycarbonyloxy, heterocyclylcarbonyloxy and heterocyclylalkylcarbonyloxy.
3. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 2 , wherein R 14 is a substituted or unsubstituted group selected from phosphonooxy, phosphonoalkyloxy, arylcarbonyloxy, arylalkylcarbonyloxy, aryloxycarbonyloxy, heterocyclylcarbonyloxy and heterocyclylalkylcarbonyloxy.
4. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 3 , wherein R 14 is a substituted or unsubstituted group selected from phosphonooxy, phosphonoalkyloxy, arylcarbonyloxy, arylalkylcarbonyloxy and aryloxycarbonyloxy.
5. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein R′ is furanylalkyl optionally substituted with one or more of halo, alkyl, haloalkyl or alkoxy.
6. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 5 , wherein the furanylalkyl is unsubstituted.
7. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, halogen, alkoxy, alkyl, and haloalkyl.
8. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 7 , wherein R 1 , R 3 and R 4 are each hydrogen.
9. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 8 , wherein R 2 is fluoro.
10. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein R 7 is hydrogen and R 8 is alkyl.
11. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, halogen, alkoxy, alkyl and haloalkyl; R 7 is hydrogen; and R 8 is alkyl.
12. The compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein R 1 , R 3 and R 4 are each hydrogen; R 2 is selected from halogen and alkoxy; R 7 is hydrogen and R 8 is alkyl; and R 13 and R 15 are each alkoxy.
13. The compound of claim 1 , which is selected from:
(Z)-4-((5-fluoro-3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenyl benzoate,
(Z)-4-((3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-5-methoxy-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenyl (4-nitrophenyl) carbonate,
(Z)-4-((3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-5-methoxy-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenyl benzoate,
(Z)-4-((3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-5-methoxy-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenyl nicotinate,
(Z)-4-((3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-5-methoxy-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenyl dihydrogen phosphate,
(Z)-(4-((3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-5-methoxy-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenoxy)methyl dihydrogen phosphate,
(Z)-4-((5-fluoro-3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenyl nicotinate,
(Z)-4-((5-fluoro-3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenyl (4-nitrophenyl) carbonate,
(Z)-4-((5-fluoro-3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenyl dihydrogen phosphate, and
(Z)-(4-((5-fluoro-3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenoxy)methyl dihydrogen phosphate,
or the corresponding (E)-isomer thereof, or pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 1 , and a pharmaceutically acceptable carrier.
15. A method of therapeutically treating a human or nonhuman mammalian patient having cancer, wherein the cancer is selected from pancreatic cancer, lung cancer, colorectal cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, head and neck cancer, endocrine cancer, uterine cancer, breast cancer, sarcoma cancer, gastric cancer, hepatic cancer, esophageal cancer, central nervous system cancer, brain cancer, hepatic cancer, germline cancer, lymphoma, and leukemia, comprising administering to said patient an anticancer effective amount of at least one compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein said at least one compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof is administered alone or in combination with an antitumor drug or radiation, wherein said antitumor drug is not a compound, (Z)- or (E)-isomer thereof, or a pharmaceutically acceptable salt thereof, of claim 1 .